Medically Reviewed by Dr. Joel Cherdack, Regenerative Medicine Physician | Houston Regenerative Medicine
Last Updated: March 2026
Key Takeaways
- When properly monitored by a qualified physician, TRT may be a safe and effective treatment for clinically confirmed low testosterone — but “safe” depends almost entirely on the quality of oversight.
- The most-cited fears — heart attacks and prostate cancer — are largely rooted in outdated or misinterpreted studies; current medical evidence paints a more nuanced picture.
- Personalized blood work, in-person lab testing, and regular clinical check-ins are the primary mechanisms that separate responsible TRT from risky, unsupervised use.
- Not everyone is a candidate. A thorough pre-treatment evaluation — including a full hormone panel and medical history review — is the essential first step.
TRT, when prescribed and monitored by a qualified physician, is considered a medically appropriate treatment for clinically diagnosed low testosterone in most healthy adult men. The risks are real, documented, and manageable — but they are not inevitable. The difference between a safe outcome and a harmful one typically comes down to one factor: the quality of clinical oversight.
If you’ve been reading conflicting headlines about testosterone therapy causing heart attacks or fueling prostate cancer, you’re not wrong to be cautious. Some of those fears have a history. But the science has moved significantly, and the outdated studies that sparked those headlines have since been reexamined, revised, or directly contradicted by larger, more rigorous research.
This guide, written from direct clinical experience treating hormone-deficient patients at our Houston clinic, will walk you through the specific risks, what the current evidence actually shows, and how a personalized, physician-supervised approach to testosterone replacement therapy is fundamentally different from the unmonitored testosterone use that generates most of the horror stories.
What Does “Safe” Actually Mean for TRT?
“Safe” in medicine is never an absolute. It’s always a risk-benefit calculation made in the context of a specific patient’s health profile, goals, and clinical picture.
For a 47-year-old man with confirmed hypogonadism — low testosterone verified by two separate morning blood draws — chronic fatigue, loss of muscle mass, and declining cognitive function, the risks of leaving low testosterone untreated may be just as significant as the risks of treatment. Untreated testosterone deficiency has been associated with metabolic syndrome, increased cardiovascular risk, reduced bone density, and diminished quality of life.
The question, then, is not “Is TRT safe in a vacuum?” It’s “Is TRT safe for this patient, managed by this protocol?” That distinction is the foundation of everything we do at Houston Regenerative Medicine.
Does Testosterone Therapy Increase the Risk of Heart Attack?
This is the fear that stops more men from pursuing treatment than any other, and it deserves a thorough answer.
What the Latest Research Actually Shows
The concern originated largely from a 2010 study published in the New England Journal of Medicine that was halted early after a higher rate of cardiovascular events was observed in a TRT group. That study was widely criticized for its methodology — it involved older men with significant pre-existing cardiovascular disease, and the testosterone doses used were not calibrated to individual patient needs.
Since then, the research landscape has shifted considerably. The landmark TRAVERSE trial, published in 2023 in the New England Journal of Medicine, was specifically designed to address cardiovascular safety. It followed over 5,000 men with hypogonadism and elevated cardiovascular risk for approximately 33 months. The trial found that testosterone therapy was non-inferior to placebo with respect to major adverse cardiovascular events —meaning it did not increase the rate of heart attacks or strokes compared to no treatment. However, the trial showed that the most notable adverse events observed were an increased risk of non-fatal arrhythmias, venous thromboembolic events, and fractures in the testosterone group compared to the placebo group.
The current consensus among major endocrinology bodies (including the American Urological Association and the Endocrine Society) is that TRT does not appear to increase cardiovascular risk in men who are properly screened and monitored.
How Monitored TRT Differs From Unregulated Use
The key word is monitored. Testosterone therapy can raise red blood cell production (hematocrit), which, if left unchecked, can thicken the blood and theoretically elevate clotting risk. This is precisely why regular blood work is not optional —it’s the mechanism that keeps treatment safe. At our Houston clinic, we track hematocrit, lipid panels, and blood pressure at every scheduled interval, adjusting dosing as needed before a problem develops.
Can Testosterone Replacement Therapy Cause Prostate Cancer?
This fear has deep roots and a complicated history.
Separating the Old Fear From the Current Evidence
For decades, the medical community operated on what’s known as the “androgen hypothesis”: the idea that testosterone “feeds” prostate cancer the way gasoline feeds a fire. This was based largely on 1940s-era research showing that castration (which eliminates testosterone) caused prostate tumor regression.
The problem is that the leap from “removing testosterone shrinks tumors” to “adding testosterone causes cancer” was never rigorously proven — and more recent research suggests the relationship is far more nuanced.
A 2016 meta-analysis published in the Journal of Urology, examining over 11,000 patients, found no statistically significant association between TRT and increased prostate cancer incidence.³ The Endocrine Society’s current clinical practice guidelines state that TRT is not recommended for men with active or recently treated prostate cancer, but that men with no evidence of prostate cancer who have a clinical need for testosterone therapy may be treated with appropriate monitoring.
That monitoring includes a baseline PSA (prostate-specific antigen) test before treatment begins, and regular PSA checks thereafter. If PSA levels rise significantly, treatment is paused, and further evaluation is initiated. This isn’t a loophole — it’s the protocol working exactly as designed.
What Are the Most Common Side Effects of TRT — and How Are They Managed?
TRT side effects are real, and any physician who tells you otherwise isn’t being straight with you. The key is that the most clinically significant ones are predictable, detectable early, and manageable with proper oversight.
The most commonly reported side effects include:
- Elevated hematocrit (polycythemia): Increased red blood cell production; monitored via regular CBC blood panels
- Testicular atrophy and reduced sperm production: A known effect of exogenous testosterone; relevant for men considering future fertility
- Acne and oily skin: Typically mild; responsive to dosing adjustments
- Fluid retention: Usually transient; resolves with dose optimization
- Sleep apnea exacerbation: TRT may worsen pre-existing sleep apnea; screening is part of our pre-treatment evaluation
- Mood changes: Some patients report initial irritability during the adjustment period; this typically stabilizes
The Role of Personalized Dosing
The majority of TRT side effects are dose-dependent. This is why a one-size-fits-all approach — common in high-volume telehealth platforms — creates unnecessary risk. We approach each patient as a unique individual, tailoring hormone replacement programs specifically to their baseline labs, symptom profile, age, and health history. A 38-year-old active professional and a 58-year-old man with metabolic syndrome do not receive the same protocol.
Why In-Person Labs Matter
There is a meaningful clinical difference between a fingerstick blood sample processed by a mail-in kit and a venous draw analyzed in our on-site Houston lab. Fingerstick tests are subject to relative higher variability and can be affected by hydration, and typically measure a narrower panel of markers. While this variability is often non significant, when we are making dosing decisions that affect cardiovascular and hormonal health, we rely on full venous panels —total and free testosterone, SHBG, estradiol, PSA, CBC, comprehensive metabolic panel— processed with clinical-grade accuracy.
Is It Safe to Be on TRT for Life?
This question weighs on men who are 35 or 40, doing the math on what “long-term therapy” actually means for their bodies over the next 30+ years.
The honest answer is that truly long-term data —spanning 20 to 30 years— is still limited, because modern, physician-supervised TRT protocols are relatively recent.
The critical variable, again, is monitoring. Men who remain on TRT long-term under our care receive comprehensive bloodwork panels at regular intervals — typically every 3 to 6 months once stable — with ongoing assessment of cardiovascular markers, prostate health, and hormone balance. The goal is not to keep testosterone “high.” It’s to keep it optimal for that individual, which means within the normal physiological range for a healthy adult male.
Long-term TRT is not a set-it-and-forget-it prescription. It is an ongoing clinical relationship.
How Often Do You Need Blood Tests While on TRT?
This is one of the most practically important questions a prospective TRT patient can ask — and the answer reveals a great deal about whether a provider is serious about patient safety.
The Clinical Monitoring Timeline
At Houston Regenerative Medicine, our standard monitoring protocol follows this general framework:
| Phase | Timing | Key Markers Assessed |
| Pre-Treatment Baseline | Before the first dose | Total & free testosterone, SHBG, estradiol, PSA, CBC, CMP, lipid panel, thyroid |
| Initial Follow-Up | 6–8 weeks post-start | Testosterone levels, hematocrit, estradiol, symptom review |
| Stabilization Check | 3 months | Full panel repeat; dosing adjustments as needed |
| Ongoing Maintenance | Every 3–6 months (stable patients) | CBC, PSA, testosterone, estradiol, cardiovascular markers |
| Annual Comprehensive Review | Yearly | Full panel + prostate exam + cardiovascular assessment |
Any provider offering TRT without this level of structured follow-up is not practicing to the current standard of care. If a telehealth platform is sending you testosterone without requiring regular bloodwork, that is a clinical red flag — not a convenience.
Telehealth TRT vs. In-Person Clinical Monitoring — Why the Difference Matters
The explosion of telehealth testosterone platforms has made access to TRT easier than ever. It has also introduced a category of risk that didn’t previously exist at this scale.
The appeal is understandable. You answer a questionnaire, submit a fingerstick blood sample, and receive a prescription within days — no office visit required. For men who are genuinely busy and genuinely suffering from low testosterone symptoms, this feels like a solution.
The problem is that the safety of TRT is not in the prescription. It’s in the monitoring. A physician who has never met you, reviewed your full medical history, or examined you in person is working with a fraction of the clinical picture. Fingerstick testosterone tests are not equivalent to venous draws. A questionnaire is not a physical exam.
We are not dismissing telehealth broadly — it has real value in many areas of medicine. But for a YMYL therapy like TRT, where cardiovascular markers, prostate health, and hormonal balance all require ongoing clinical judgment, in-person care with on-site lab capabilities represents the gold standard. It’s the approach we’ve built our practice around, and it’s the reason our patients can pursue this therapy with genuine confidence rather than hope.
Who Is NOT a Good Candidate for TRT?
One of the clearest signals that a clinic prioritizes patient safety over sales volume is its willingness to say “not yet” or “not for you.” There are real contraindications to TRT, and any responsible evaluation must screen for them.
TRT is generally not recommended for men who have:
- Active or recently treated prostate cancer — testosterone may stimulate residual cancer cells
- Active breast cancer — rare in men, but a clear contraindication
- Severe, untreated sleep apnea — TRT may worsen respiratory events during sleep
- Hematocrit above 50–54% — elevated baseline red blood cell count increases clotting risk
- Uncontrolled heart failure — fluid retention associated with TRT can exacerbate the condition
- Recent cardiovascular event (within 3–6 months) — requires specialist clearance before initiating therapy
- Desire for near-term fertility — TRT suppresses sperm production; alternative treatments may be more appropriate
This list is not meant to be alarming — most men who are symptomatic and seeking evaluation will not have these contraindications. It’s meant to illustrate that responsible TRT begins with a thorough medical evaluation, not a checkbox form.
Frequently Asked Questions
Does TRT cause hair loss or baldness?
TRT may accelerate hair loss in men who are genetically predisposed to male-pattern baldness, as testosterone converts to dihydrotestosterone (DHT), which can affect hair follicles. It does not cause hair loss in men without a genetic predisposition. If this is a concern, it can be discussed and, in some cases, addressed with adjunct therapies as part of your personalized treatment plan.
Can your body naturally produce testosterone again after stopping TRT?
In most cases, yes — though recovery time varies. Exogenous testosterone suppresses the body’s natural production via the hypothalamic-pituitary-gonadal (HPG) axis. After stopping TRT, most men see natural production resume within 3 to 12 months, though recovery may be slower in men who have been on therapy for extended periods. Post-cycle protocols — including medications like clomiphene or hCG — may be used to support faster recovery in appropriate patients.
Is TRT the same as anabolic steroid use?
No. Physician-prescribed TRT is designed to restore testosterone to the normal physiological range — typically 400 to 900 ng/dL — not to elevate it above what a healthy adult male would naturally produce. The supraphysiological doses used in non-medical anabolic steroid use are categorically different in both intent and risk profile.
If you’ve read this far, you’re doing exactly what a thoughtful patient should do: gathering objective, medically grounded information before making a healthcare decision. The next step isn’t a commitment to treatment. It’s a conversation.
At Houston Regenerative Medicine, we offer a free initial consultation with our clinical team. We’ll review your symptoms, discuss your health history, and (if appropriate) order the comprehensive bloodwork needed to determine whether clinically significant testosterone deficiency is contributing to what you’re experiencing. No pressure. No predetermined outcome. Just an honest clinical assessment.
Understanding Testosterone Replacement Therapy
